GLP-1 Receptor Antagonism: A New Frontier in Cardiovascular Health

GLP-1 Receptor Antagonism: A New Frontier in Cardiovascular Health

Cardiovascular diseases are still among the leading causes of mortality and morbidity in the world. To address this critical issue, the past decade has witnessed a surge in cardiovascular outcome trials focused on evaluating the cardiovascular safety and efficacy of various drugs. One class of drugs that has gained significant attention is the glucagon-like peptide-1 receptor agonists (GLP-1 RA). In this online course, Dr. Herbert D. Aronow discuss the novel cardiovascular applications of GLP-1 RA drugs in the assessment and treatment of cardiovascular diseases.

  • Provider:Baptist Health South Florida
  • Activity Link: https://cmeonline.baptisthealth.net/node/36349
  • Start Date: 2024-08-01 05:00:00
  • End Date: 2024-08-01 05:00:00
  • Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
  • Commercial Support: No
  • Activity Type: Enduring Material
  • CME Finder Type: Online Learning
  • Fee to Participate: No, it's free
  • Measured Outcome: Learner Competence, Learner Knowledge
  • Provider Ship: Directly Provided
  • Registration: Open to all
«
»
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments

Warning: file_put_contents(/nas/content/live/sleepliteracy/wp-content/uploads/wpdiscuz/cache/comments/.htaccess): Failed to open stream: Permission denied in /nas/content/live/sleepliteracy/wp-content/plugins/wpdiscuz/utils/class.WpdiscuzCache.php on line 161
0
Would love your thoughts, please comment.x
()
x

Contact us

If you want to join leaders who will shape what Americans think about sleep.

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.

Sign up for the expert list

for media inquiries

Name(Required)
Sign Up
This field is for validation purposes and should be left unchanged.